A Dose Escalation Phase 1 Study of HXN5003 in Healthy Participants

NCT07549750 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

28

Enrollment

INDUSTRY

Sponsor class

Conditions

Atopic Dermatitis

Interventions

DRUG: HXN5003
DRUG: Placebo

Sponsor

Helixon Biotechnology (Suzhou) Co., Ltd